Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Epirubicin
Drug ID BADD_D00784
Description An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Indications and Usage For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Marketing Status approved
ATC Code L01DB03
DrugBank ID DB00445
KEGG ID D07901
MeSH ID D015251
PubChem ID 41867
TTD Drug ID D0C9XJ
NDC Product Code Not Available
UNII 3Z8479ZZ5X
Synonyms Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 56420-45-2
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Renal failure20.01.03.0050.000112%Not Available
Respiratory distress22.02.01.0120.000112%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000168%
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Shock24.06.02.002--Not Available
Sinus tachycardia02.03.03.010--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin necrosis23.03.03.011--Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000168%
Stomatitis07.05.06.0050.000168%
Tachycardia02.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000571%Not Available
Thrombocytopenia01.08.01.0020.000280%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Ulcer08.03.06.001--Not Available
Ureteric obstruction20.06.01.005--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.010--
Viral infection11.05.04.001--Not Available
Vomiting07.01.07.0030.000504%
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
Emotional distress19.04.02.0080.000470%Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene